Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1125)	4/17/2002 4:41:14 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 2243

I am near to recommending CRXL for T/FIF. Holding it would require some stamina, as revenues--though diverse--are back loaded and of modest (royalty) amount. If pharma takes down one more Mab....then I'll advocate. (I would personally like to see the vitronectin Mab licensed.) But if the 7 Mabs already raised and now available for license remain orphans over the next 6 months or, worse, one or two become self-developed, then it's a no go. Will be watching. Wilder